Shares Issued
As at 6 March 2024, the number of shares in issue was 1,341,815,988.
Significant Shareholders
As at 6 March 2024
None known at present time except for Director shareholdings (see below).
Director Shareholdings
As at 6 March 2024
Director | Number | Ordinary Shares % |
---|---|---|
Alexis Sandler | 75,090,685 | 5.60 |
Dr Vladislav Sandler | 41,544,677 | 3.10 |
Peter Redmond | 5,596,270 | 0.42 |
Shares Not In Public Hands
Insofar as it is aware, as at 6 March 2024, 14.25% of the Company’s securities were not in public hands.
UK City Code On Takeovers And Mergers
The Company is subject to the provisions of the City Code on Takeovers and Mergers.
Shareholder Circulars
Annual and Half Year Reports, together with historical general meeting notices, blank proxy voting forms, and other shareholder circulars, may be found here: Annual and Half Year Reports.
Most recent shareholder circular:
2 June 2023 | Notice of Annual General Meeting to be held on 30 June 2023 |
Other Exchanges And Trading Platforms
Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.